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LETTER TO THE EDITOR
Fatal heart failure in a young adult female sarcoma patient treated with
pazopanib
Vicky L. M. N. Soomers, Ingrid M. E. Desar, Nielka P. van Erp, Jeroen Verwiel, Suzanne E. J. Kaal and
Winette T. A. van der Graaf
Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands
Soft tissue sarcomas are rare malignancies of mesenchymal
origin. Pazopanib is an oral tyrosine kinase inhibitor, target-
ing vascular endothelial growth factor receptors (VEGF1-2-3),
platelet-derived growth factor receptors (PDGFR-a and -b)
and stem cell factor receptor (c-KIT) and is approved for
patients with metastatic non-adipocytic soft tissue sarcoma
after anthracycline-based chemotherapy [1].
Pazopanib is usually well tolerated, with fatigue, diarrhea,
nausea, weight loss and hypertension as the most frequently
described side effects [1]. Symptomatic left ventricular sys-
tolic dysfunction is a rare side effect, occurring in 1% of
patients with soft tissue sarcoma, and fatal outcome has
been described once [2].
In this case report, we describe fatal congestive heart fail-
ure and hepatotoxicity in a young patient, occurring four
weeks after commencing pazopanib, with high serum drug
levels of pazopanib.
Case presentation
A 27-year-old woman presented elsewhere with potentially
resectable liver metastases of a leiomyosarcoma of the colon.
Unfortunately, after one cycle of induction chemotherapy
with doxorubicin and ifosfamide, bone metastases became
overt and were histologically proven, which made a curative
treatment intent no longer a realistic option. Therefore, she
continued with monotherapy doxorubicin with a palliative
intention. After five further courses of doxorubicin, radio-
logical evaluation showed stable disease. Treatment was dis-
continued after a cumulative doxorubicin dosage of
450mg/m2. Six months later, pazopanib 800mg OD was initi-
ated because of progressive disease. The patient was referred
for a second opinion. On presentation, she had been using
pazopanib for four weeks, she was complaining of grade 2
fatigue, grade 2 anorexia, grade 3 stomatitis, grade 2 hand–
foot syndrome and grade 2 diarrhea. Her lab results showed
a decrease in renal function with a creatinine of 117 umol/l
and raised liver enzymes (Table 1). The adverse events were
considered as pazopanib related and therapy was discontin-
ued. She did not use any other medication.
Two days later, she presented critically ill at the emer-
gency department with progressive dyspnea and severe
fatigue since one day. Physical examination revealed that she
had a low blood pressure of 67/49mmHg with a heart rate
of 125/min. Her respiratory rate was 24/min and oxygen sat-
uration with room air was 99%. Auscultation of heart and
lungs was unremarkable, her liver was not palpable, there
was no edema or raised central jugular vein pressure. The
electrocardiogram showed a sinus tachycardia with a left axis
and left bundle branch block. We had no previous
electrocardiograms.
Lab results showed a hemoglobin of 11.3mmol/l, leuko-
cytes of 8.7 109/l and trombocytes of 41 109/l. Her liver
enzymes had tripled compared to the results two days earlier
(Table 1). CRP was 29mg/l, lactate 7.3mmol/l. Coagulation
parameters showed a PT of 36 sec, APTT 45 sec, D-dimer
26,920 ng/ml and fibrinogen 1050mg/l.
A CT scan excluded pulmonary embolism and showed sta-
ble disease, without pulmonary or new intrahepatic abnor-
malities. Cardiac ultrasound showed a dilated left and right
ventricle with an ejection fraction of 20–25%.
Upon admission, nearly 72 hours after the last dosage of
pazopanib, the patient still had high concentrations of pazo-
panib in her blood (Table 1). Pazopanib half-life was deter-
mined based on a second serum level on day two,
corresponding with a half-life of 63.5 hours (population aver-
age is 31 hours). This implied that the serum levels on
admission corresponded with at least a trough level (a level
that is taken at 24 hours after a drug is taken OD) of 65mg/l.
Extrapolation of the serum level on admission to the trough
level should be interpreted with caution, since the elimin-
ation might have decreased in the course of time, due to
worsening of metabolic capacity as a consequence of wor-
sening of liver impairment. Nevertheless, even with the most
conservative approach the trough level on admission can be
regarded as toxic. Serum levels >20.5mg/l are associated
with more efficacy, while levels >46mg/l are associated with
more toxicity [3].
She was admitted to the intensive care unit with serious
and most likely pazopanib induced heart failure. She received
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vasopressive treatment and treatment with N-acetylcysteine
[4]. Viral causes of acute liver failure were excluded. A second
cardiac ultrasound showed a non-dilated left ventricle with
an ejection fraction of 10–15%, despite high levels of ino-
tropic medication.
Unfortunately, despite maximal supportive treatment on
the IC unit, including hemodynamic and ventilatory support,
the patient died seven days after admission.
Discussion
We described a 27-year-old patient without cardiovascular
history or risk factors, except for previous doxorubicin admin-
istration, who developed fatal congestive heart failure during
treatment with pazopanib in conjunction with unexplained
high trough levels.
A meta-analysis of 10,647 patients treated with several
tyrosine kinase inhibitors (TKI) including pazopanib, showed
a 2.4% risk of congestive heart failure versus 0.75% in the
non-TKI group [5]. High-grade (3 and 4, no fatal cases
reported) congestive heart failure occurred in 1.19% of
patients receiving TKI, versus 0.65% in the non-TKI group.
The relative risk of all grade congestive heart failure was 2.69
(p .001) and for high-grade 1.65 (p ¼ .227). Median therapy
duration was 23 weeks for all TKIs, and 7.4 months and 16.4
weeks for the two pazopanib trials. Remarkably, the congest-
ive heart failure in our patient developed as early as 4 weeks
after start of pazopanib.
Hypothetically the previous treatment with doxorubicin
could contribute to the occurrence of heart failure, although
the PALETTE trial showed a 1% rate of symptomatic left ven-
tricular systolic dysfunction in people treated with pazopanib,
while 99% of patients had received anthracyclines [1].
This severe heart failure has not been reported for pazo-
panib before. The absence of highly increased bilirubin levels
and encephalopathy plead against toxic hepatitis. In combin-
ation with the rapid recovery, it is most likely this was hyp-
oxic hepatitis secondary to cardiac failure after treatment
with pazopanib and doxorubicin. As the liver enzymes were
only slightly raised on day 2, we do not think that liver dys-
function explains the prolonged high serum trough levels of
pazopanib.
Hepatotoxicity is a well-known adverse event of pazopa-
nib. A meta-analysis of all pazopanib containing trials showed
a 42% incidence of all grade ALT increase, and an 9.4% inci-
dence of high-grade ALT increase [6]. There has been little
understanding of the underlying mechanism. One case series
of two patients showed mild active cholestatic hepatitis with
inflammation that predominantly involved portal tracts [7].
However, in this case we concluded that liver failure most
likely had a hypoxic origin and was secondary to cardiac fail-
ure, although a direct hepatoxic effect of pazopanib due to
high trough levels cannot be excluded.
Conclusions
This case shows a fatal outcome of heart failure in a young
female patient who had unexplained, high exposure to pazo-
panib. Next to monitoring left ventricular ejection fraction,
therapeutic drug monitoring may be helpful in the future to
adapt pazopanib dosages in a timely fashion.
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Table 1. Pazopanib serum levels and course of liver enzymes.
First presentation
Day 2
Emergency
department Day 0 Day 2 Day 7
Pazopanib (mg/l) – 37.70 25.23 –
ALT (<35 U/l) 272 1050 3292 716
AST (<30 U/l) 537 2138 10390 532
LDH (<250 U/l) 758 2211 8860 948
gGT (<40 U/l) 20 25 20 26
AF (<100 U/l) 125 126 94 86
Bilirubin (17 umol/l) 22 48 37 127
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